Abbott in Talks to Acquire Exact Sciences — Summary
Abbott Laboratories is negotiating to acquire cancer diagnostics company Exact Sciences, according to media reports. A deal could be announced within days, but negotiations remain fluid and delays or a collapse are possible. Exact Sciences’ shares rose nearly 25%, valuing the company above $13 billion, while Abbott’s shares fell about 3% in afternoon trading. Abbott is reviewing potential transaction terms. Exact Sciences is best known for Cologuard, a non-invasive colorectal cancer screening test that can be done at home by mailing a stool sample to a lab.
Exact Sciences is best known for Cologuard, its flagship non-invasive colorectal cancer screening test. Unlike colonoscopy—which requires bowel preparation, sedation and a hospital visit—Cologuard can be completed at home, with patients mailing a stool sample to a laboratory for analysis.
Key Facts
- Abbott Laboratories is in advanced discussions to acquire Exact Sciences.
- A deal could be announced within days; negotiations remain fluid.
- Exact Sciences’ market value exceeded $13 billion after the news.
- Abbott’s stock declined about 3% in afternoon trading.
- Cologuard is Exact Sciences’ flagship product—home-based, non-invasive colorectal cancer screening.
Context and Implications
The potential acquisition would combine Abbott’s broader diagnostics portfolio with Exact Sciences’ specialized cancer tests. This could impact competition in the cancer diagnostics space and influence accessibility and pricing of screening options. Official confirmations or denials from the companies are not provided in the text.
Author’s Summary
Abbott pursues an acquisition of Exact Sciences, signaling consolidation in cancer diagnostics; rapid potential closure accompanies stock movements and product-focused synergies from Cologuard.
More News
- [X1.9 solar flare erupts from Sun, causing brief radio blackout]
- Ryan Serhant says his daughter will have to ‘figure it out’ as housing market resets for Gen Z
- Owning Manhattan's Ryan Serhant, 41, opens up about his ' addiction' as he admits: 'I do honestly have withdrawals'
- The Icy Embrace: A Guide to Iceland’s Winter Wonders
- Northern lights may shine in the sky over Canada Wednesday night
- Northern lights may appear in 15 states, including Wisconsin, on Dec. 3 and 4
- Where to see northern lights as geomagnetic storm hits earth
- West Africa fights back against Boko Haram
- Owning Manhattan Star Ryan Serhant on His Emotional Breakdown, Growth and Zohran Mamdani’s Impact
- Kanye West, Bianca Censori visit South Korea after Kim Kardashian’s new claims